Assessment of the Effect of Captopril Versus Combination of Captopril and Pentoxifylline on Reducing Proteinuria in Type 2 Diabetic Nephropathy

• Status: Completed
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Diabetic nephropathy is the most common cause of ESRD and has a great impact on mortality and morbidity of diabetic patients. Despite renoprotective effect of ACE inhibitors in diabetic patients they can not hinder the progression of renal disease completely. Pentoxifylline as a TNFa blocker may hinder progression of diabetic nephropathy in combination of captopril.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shiraz University of Medical Sciences
• Treatments: Captopril; Pentoxifylline

Criteria

Inclusion Criteria:

1. Absence of kidney or urinary tract disease

2. Absence of high blood pressure OR Controlled blood pressure (≤140/90) with medication other than ACE inhibitors and/or non dihydropyridine calcium channel blockers

3. A well controlled blood sugar level (HbA1c≤7.5%)

4. Adhering to the diet protocol for patients with renal disease

Exclusion Criteria:

1. NYHA functional class III, IV

2. Valvular heart disease

3. Unstable angina, myocardial infarction, cerebrovascular accidents

4. Psychiatric disease

5. Prior allograft kidney transplant

6. Acute illness

7. Infectious disease including urinary tract infection

8. Leukocytosis or any febrile illness at enrollment

9. Prior history or development of any form of malignancy

10. History of alcohol or drug abuse or smoking

11. Pregnancy

12. Need for surgery during the study

13. Allergy to derivatives of methyl xanthines

14. Current Pentoxyphilline use